Fibrostenotic Inflammatory Bowel Disease: A Cinderella Story
Intestinal fibrosis in inflammatory bowel disease (IBD) leading to stricture formation, intestinal obstruction and need for surgical intervention remains one of the largest unresolved clinical challenges in IBD. Despite the emergence of novel anti-inflammatory drugs the incidence of stricture formation and surgery remained largely unchanged. Challenges in testing anti-fibrotic compounds have so far prevented progress in this area, but recent development put clinical trials for anti-fibrotic compounds into reach.
KeywordsStricture Crohn’s Surgery Anti-fibrotic Obstruction
This work was supported by grants from the National Institutes of Health [T32DK083251, P30DK097948 Pilot Feasibility Study, K08DK110415] and the European Crohn’s and Colitis Foundation to F.R.
Conflicts of Interest
F.R. Consulting: UCB, Celgene, Samsung, Roche, Pliant, Thetis, Boehringer-Ingelheim, Helmsley; AdBoards: AbbVie, UCB, Receptos, RedX, Celgene; Speakers Bureau: AbbVie.
- 7.Hughes G, Toellner H, Morris H, et al. Real world experiences: Pirfenidone and Nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5. https://doi.org/10.3390/jcm5090078.